Overview

Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to describe the activity and toxicity of a new formulation of cytarabine called liposomal cytarabine given into the central nervous system for the treatment of central nervous system localization of acute lymphoblastic leukemia (ALL) in children and adolescents.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute, Naples

Collaborators:

Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Santobono-Pausilpon Hospital
University of Bologna

Treatments:

Cytarabine